VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

PRICE: 0 CENTS

Wednesday, January 7, 2026

Stevanato Group S.p.A.

STVN · New York Stock Exchange

Market cap (USD)$5.7B
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryIT
Data as of
Moat score
59/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Stevanato Group S.p.A. provides primary packaging (vials, syringes, cartridges, and ready-to-use systems) and related services for injectable drugs and diagnostics, and also sells engineering equipment (inspection, assembly, packaging/serialization, and glass converting). The moat is strongest in high-value solutions where regulatory qualification and switching costs, proprietary manufacturing know-how, and trusted quality systems support premium pricing. The core containment and delivery business is more competitive but still benefits from qualification friction and multi-year supply agreements. The engineering segment adds installed-base service revenue and cross-selling via an integrated one-stop-shop offering.

Primary segment

Other Containment and Delivery Solutions

Market structure

Competitive

Market share

HHI:

Coverage

3 segments · 7 tags

Updated 2026-01-05

Segments

High-Value Solutions

High-value primary packaging and integrated solutions for injectable drugs

Revenue

38.3%

Structure

Oligopoly

Pricing

strong

Share

Peers

1SXP.DEWSTGXI.DE8086.T+2

Other Containment and Delivery Solutions

Standard primary packaging and related services for injectable drugs and diagnostics

Revenue

46.3%

Structure

Competitive

Pricing

weak

Share

Peers

1SXP.DEWSTGXI.DE8086.T+2

Engineering

Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment

Revenue

15.4%

Structure

Competitive

Pricing

moderate

Share

Peers

Moat Claims

High-Value Solutions

High-value primary packaging and integrated solutions for injectable drugs

Revenue share computed from FY2024 Form 20-F revenue breakdown: EUR 422.3m high-value solutions out of EUR 1,104.0m total revenue. Key glass tube suppliers disclosed in the same filing include Schott, NEG, Nipro, and Corning.

Oligopoly

Design In Qualification

Demand

Strength

Durability

Confidence

Evidence

Primary packaging is part of the drug product and regulatory filings; changing suppliers requires customer re-qualification and time.

Erosion risks

  • Dual-sourcing reduces lock-in
  • Competing container formats/materials (polymer, alternative delivery)
  • Major customers use purchasing leverage

Leading indicators

  • Share of customer programs using Stevanato RTU formats
  • Churn/qualification losses on new molecule wins
  • Gross margin and price/mix in high-value portfolio

Counterarguments

  • Large pharma can and does qualify multiple suppliers
  • Competitors can replicate performance features with enough time and capex

Capex Knowhow Scale

Supply

Strength

Durability

Confidence

Evidence

High-value products rely on proprietary processes and specialized manufacturing; scale/capacity investments support innovation and delivery reliability.

Erosion risks

  • Competitor capacity additions narrow supply tightness
  • Process innovations diffuse over time
  • Execution risk in ramping new plants/lines

Leading indicators

  • Yield/scrap and customer complaint rates
  • On-time delivery and capacity utilization at new sites
  • R&D output (new platforms) and adoption

Counterarguments

  • Large competitors can invest comparable capex and hire expertise
  • Customer specs may standardize, reducing differentiation

De Facto Standard

Network

Strength

Durability

Confidence

Evidence

EZ-Fill ready-to-use systems are designed to be compatible with existing fill-finish lines; broad installed compatibility supports adoption inertia.

Erosion risks

  • Alternative RTU standards from rivals gain adoption
  • Equipment upgrades reduce compatibility advantage

Leading indicators

  • Installed base of lines qualified for Stevanato RTU formats
  • Share of RTU vs bulk formats in customer demand

Counterarguments

  • Industry standard language is self-assessed; rivals also offer RTU platforms
  • Fill-finish OEMs can support multiple RTU formats

Brand Trust

Demand

Strength

Durability

Confidence

Evidence

In regulated injectable supply chains, long track record, reliability, and audited quality systems support preferred-supplier status.

Erosion risks

  • Quality incidents/recalls damage reputation
  • New entrants with strong QA win share
  • Customer diversification away from single suppliers

Leading indicators

  • Audit findings and recall/complaint metrics
  • Top-customer retention and new molecule wins
  • Net promoter / preferred supplier status (if disclosed)

Counterarguments

  • Reputation can shift quickly after quality issues
  • Big pharma will still pressure price even with trusted suppliers

Other Containment and Delivery Solutions

Standard primary packaging and related services for injectable drugs and diagnostics

Revenue share computed from FY2024 Form 20-F revenue breakdown: EUR 511.4m other containment/delivery solutions out of EUR 1,104.0m total revenue. Key glass tube suppliers disclosed in the same filing include Schott, NEG, Nipro, and Corning.

Competitive

Design In Qualification

Demand

Strength

Durability

Confidence

Evidence

Even for more standard components, regulatory filings and qualification create switching friction and favor incumbent suppliers.

Erosion risks

  • Standard components commoditize
  • Customers qualify multiple suppliers

Leading indicators

  • Customer concentration and multi-sourcing trends
  • Pricing vs raw material inflation pass-through

Counterarguments

  • Commodity products are easier to dual-source than specialized platforms

Long Term Contracts

Demand

Strength

Durability

Confidence

Evidence

Multi-year master supply agreements and drug-life-cycle purchasing patterns provide revenue stability and reduce spot competition.

Erosion risks

  • Contract renegotiations in downturns
  • Customer destocking/inventory cycles

Leading indicators

  • Backlog level and book-to-bill
  • Renewal/price reset outcomes

Counterarguments

  • Large customers can renegotiate pricing at renewal and shift volumes

Operational Excellence

Supply

Strength

Durability

Confidence

Evidence

Consistent global quality systems and high audit frequency support reliability and lower total cost of ownership for customers.

Erosion risks

  • Quality failures reduce differentiation
  • Rivals match QA and automation

Leading indicators

  • Complaint rate, rejects, and on-time delivery
  • Gross margin vs peers in commodity categories

Counterarguments

  • Most credible suppliers in this industry run strong QA systems; excellence may not be unique

Engineering

Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment

Revenue share computed from FY2024 Form 20-F external customer revenue: EUR 170.3m out of EUR 1,104.0m total revenue.

Competitive

Service Field Network

Supply

Strength

Durability

Confidence

Evidence

Installed base of equipment drives recurring after-sales revenue (maintenance, spare parts, optimization, upgrades).

Erosion risks

  • Third-party service providers capture service work
  • Customers internalize maintenance capabilities

Leading indicators

  • After-sales revenue mix within Engineering
  • Installed base growth and service attach rates

Counterarguments

  • Equipment buyers can multi-source service and spare parts depending on contract terms

Capex Knowhow Scale

Supply

Strength

Durability

Confidence

Evidence

Specialized know-how in GMP-compliant automation, inspection (incl. AI), and precision glass forming lines; project-based delivery capabilities matter.

Erosion risks

  • Competing OEMs match features (AI inspection, modular lines)
  • Project execution overruns hurt reputation

Leading indicators

  • Backlog conversion and project margins
  • Win rates on complex inspection/assembly programs

Counterarguments

  • Automation/inspection markets have many capable vendors and rapid tech diffusion

Scope Economies

Supply

Strength

Durability

Confidence

Evidence

Bundled offering across primary packaging + equipment + services enables cross-selling and one-stop-shop value proposition for customers.

Erosion risks

  • Customers prefer best-of-breed point solutions
  • Internal re-org disrupts cross-selling

Leading indicators

  • Attach rate of equipment in accounts that buy packaging
  • Engineering backlog sourced from existing packaging customers

Counterarguments

  • Many customers separate equipment procurement from packaging sourcing to avoid vendor lock-in

Evidence

sec_filing
Stevanato Group S.p.A. Form 20-F (FY ended December 31, 2024)

The containment and delivery solution is included as part of the regulatory filings required before commercialization.

Regulatory integration raises switching costs and extends qualification cycles.

sec_filing
Stevanato Group S.p.A. Form 20-F (FY ended December 31, 2024)

Although changing providers can be a lengthy process for our customers...

Company describes time costs to change providers, supporting qualification-driven stickiness.

sec_filing
Stevanato Group S.p.A. Form 20-F (FY ended December 31, 2024)

We rely on a unique set of proprietary manufacturing processes to drive product innovations...

Signals process know-how and manufacturing capability as a barrier to entry.

sec_filing
Stevanato Group S.p.A. Form 20-F (FY ended December 31, 2024)

Due to the technical complexity...we enjoy premium pricing...

Premium pricing is consistent with differentiated products supported by know-how/capex.

sec_filing
Stevanato Group S.p.A. Form 20-F (FY ended December 31, 2024)

...manufacturing technologies are the industry standard for ready-to-fill vials and cartridges...

Company asserts standard-like positioning and cites broad fill-finish line compatibility.

Showing 5 of 13 sources.

Risks & Indicators

Erosion risks

  • Dual-sourcing reduces lock-in
  • Competing container formats/materials (polymer, alternative delivery)
  • Major customers use purchasing leverage
  • Competitor capacity additions narrow supply tightness
  • Process innovations diffuse over time
  • Execution risk in ramping new plants/lines

Leading indicators

  • Share of customer programs using Stevanato RTU formats
  • Churn/qualification losses on new molecule wins
  • Gross margin and price/mix in high-value portfolio
  • Yield/scrap and customer complaint rates
  • On-time delivery and capacity utilization at new sites
  • R&D output (new platforms) and adoption
Created 2026-01-05
Updated 2026-01-05

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.